BKIDC-1553

BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research[1].

Product Specifications

CAS Number

[1951431-34-7]

UNSPSC

12352005

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bkidc-1553.html

Concentration

10mM

Purity

99.65

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

OC(C)(CN1N=C(C2=C1N=CN=C2N)C3=CC4=C(C=C(C=C4)OC5CC5)C=C3)C

Molecular Formula

C22H23N5O2

Molecular Weight

389.45

References & Citations

[1]Uo T, et al. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355.